OS Therapies Inc — Form 8-K

OS Therapies Incorporated signed a Securities Purchase Agreement on June 30, 2026, with Leonite Fund I, LP for a senior secured convertible promissory note with principal amount up to $10,000,000, funded in tranches. The first tranche is $1,600,000 (net $1,565,000 after $35,000 in Leonite's legal fees). The note carries 9% annual interest, 7.5% original issue discount per tranche, converts at $2.05/share, includes 1,750,000 warrant shares at $2.85 exercise price, and 275,000 direct equity shares. The note matures 9 months per tranche (max 24 months from issue). Leonite receives extensive protective covenants, liquidated damages provisions, registration rights, participation/ROFR rights, and holds a first-priority security interest in substantially all company assets excluding intellectual property.